ABHD6 is a transmembrane serine hydrolase that functions as a monoacylglycerol lipase with preferential activity toward medium-chain saturated monoacylglycerols, particularly the endocannabinoid 2-arachidonoylglycerol (2-AG) 1. The enzyme plays a crucial role in endocannabinoid signaling by regulating 2-AG abundance in both central and peripheral tissues, thereby modulating neurotransmission, inflammation, and metabolic processes 2. ABHD6 also exhibits lysophosphatidyl lipase activity and serves as the major enzyme for bis(monoacylglycero)phosphate catabolism in late endosomes and lysosomes 1. The enzyme's biological significance extends beyond cannabinoid metabolism, as it regulates insulin secretion, adipose browning, food intake, and has been implicated in autoimmune disorders, neurological diseases, and cancer 3. Recent studies have identified ABHD6 as a therapeutic target, with highly selective inhibitors showing promise in preclinical models of epilepsy, neuropathic pain, inflammation, and Type-2 diabetes 4. The enzyme's dual role in lipid metabolism and receptor trafficking makes it particularly relevant for treating devastating diseases while potentially avoiding the side effects associated with complete blockade of primary 2-AG hydrolases 2.